CardioOne, a startup built at Redesign Health, partners with independent cardiology practices to help them transition to value-based care. On Monday, the company announced it has raised $8 million in seed funding and has three new partners.

Geisinger is launching a pilot program in partnership with virtual heart failure monitoring startup Bodyport. About 200 of the health system’s heart failure patients will be using Bodyport’s cardiac scale at home — the scale uses sensors to measure a person’s metrics of heart function and body fluid status after they stand on it for about 20 seconds.

Rich multimedia content, chatbots and human interaction all play important roles in helping new health technologies become part of a patient’s lifestyle.

Israeli medical device developer Magenta Medical recently closed a $55 million financing round. The new funding will be used primarily to help Magenta attain FDA approval for its flagship product — a percutaneous left ventricular assist device called Elevate.

The shifting of services to outpatient settings will likely cause hospitals to unwind their contractual relationships with cardiologists, sending the physicians back into private practice. Astute hospital administrators will have already anticipated the migration of cardiologists away from hospital inpatient care and started to prepare for a different type of alignment with cardiologists.

Alviss.ai CEO and Founder Dr. Pavel Overtchouk talks about how the company’s stroke prediction software seeks to be the first attempt to apply predictive medicine to cardiovascular interventions and heart surgery.

Medical imaging company Genetesis recently closed a $17.5 million Series C funding round, bringing its total funding to date to more than $40 million. Most of the funds will go toward clinical trials for the company’s 5-minute test to detect ischemic heart disease, which uses magnetocardiography. Genetesis anticipates the test entering the market in early 2023.

Th FDA granted another 510(k) clearance to iRhythm Technologies for its AI-powered software system designed for use with Verily’s irregular pulse tracking watch. The clearance is for an algorithm that categorizes patients’ AFib by analyzing how much of it they experience over time.

An infographic illustrates how Medtronic’s AccuRhythm AI suppresses false alerts while maintaining sensitivity.

San Francisco-based Blumio and Saint Paul, Minnesota-based NxGenPort tied for the top prize in the Remote Patient Monitoring and Smart Devices track of INVEST Pitch Perfect, the startup competition integral to MedCity News’ INVEST conference. Here is an in-depth look at each company.

The ViVE conference last week was a refreshing collection of discussions exploring how much progress has been made in healthcare transformation and the enormous amount of work yet to be done.

A study published in Circulation showed that the Apple Watch’s ECG detected some arrhythmias other than atrial fibrillation. The device is currently cleared to take ECGs and general irregular pulse alerts, which could indicate potential cases of atrial fibrillation.

Hillrom will buy Bardy Diagnostics, a startup that makes a wearable ECG patch, for $375 million in cash.

Boston Scientific will acquire remote cardiac monitoring company Preventice for $925 million in cash and up to $300 million in milestone payments. The deal is expected to close in mid-2021.

In this webinar on Feb. 10,
healthcare experts from Desert Oasis Healthcare and iRhythm Technologies will discuss how Zio monitors, designed to be worn for longer duration than holter monitors, represent a new standard of care in remote cardiac monitoring.

A young UK startup is collaborating on a research study with Mayo Clinic to use an FDA-cleared automated echocardiogram assessment and quantification tool to unlock the mysteries of how Covid-19 attacks the heart.

Heartbeat Health, a digital health startup to help patients manage heart disease, raised $8.2 million in series A funding. The platform offers telehealth visits and helps patients keep track of their heart health by pulling in metrics from wearables and other devices.

The new Japanese reimbursement policy will go into effect on Dec. 1 and follows positive coverage decisions by Medicare and the United Kingdom’s National Health Services.

The company’s new Apple Watch can perform ECGs, detect atrial fibrillation and contact emergency services in the case of a fall.

CNBC reports the tech giant has halted talks with U.S. hospitals to share anonymized patient information, and Facebook said no data has been shared or analyzed.

If the eyes are the window to the soul, Google thinks it’s proven that images of the retina can offer a window on the state of the heart.

Cardiogram’s study with University of California San Francisco recruited 14,011 participants who access the Cardiogram app through Apple Watch or Android smartwear. 

AliveCor’s Kardiaband is designed to help consumers manage the task of detecting Afib, a form of heart arrhythmia and will help Apple bolster its relevance to healthcare.

In addition to the acquisition, Quest Diagnostics and the Cleveland Clinic have embarked on a strategic collaboration that will evaluate biomarkers for various diseases, with Quest developing tests for some of them.

Genetesis and Analytics 4 Life have developed non-invasive approaches to cardiac diagnostics.

The report found that nearly 73,000 people on Medicare had one of the seven devices replaced because of recalls, premature failures, medically necessary upgrades or infections.

Apple COO Jeff Williams noted that the company has been working on improvements to its heart rate monitoring technology over the past couple of years and claimed that Apple’s heart rate monitor is the most widely used in the world.

A recent report from Reaction’s Research Cloud takes a look at how one medical specialty is slow to implement speech recognition technology.

The analysis provides a critical piece of the puzzle behind more than 100 severe — and sometimes fatal — infections in cardiac surgery patients worldwide since 2013, researchers said.

The device can be used in a doctor’s office and could be prescribed to heart disease patients to support remote monitoring and reduce readmissions.